Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa

Table 4 Recurrences in patients treated with chemoradiotherapy

PS	Location	ER	RT field	Dose	Recurrence site	DFS	Treatment for recurrence
0	Mt	−	ENI	60.0	Local	0	Surgery
1	Mt	+	ENI	28.0	Lung	6.1	Surgery
0	Ut	−	Non-ENI	40.0	Local	7.2	ESD
0	Mt	+	ENI	40.0	#104R	13.1	Chemotherapy
0	Lt	+	ENI	39.6	#3, #7	15.3	Surgery
0	Ut	+	ENI	50.4	#101R	19.8	Chemotherapy
0	Mt	+	ENI	40.0	#109R	22.5	Chemotherapy
0	Mt	+	ENI	39.6	#104R	28.5	Chemotherapy
0	Mt	+	ENI	65.0	#104R	30.7	Chemotherapy
0	Mt	+	Non-ENI	40.0	#104R	31.0	Chemotherapy
0	Mt	+	ENI	39.6	Local	43.2	ESD
1	Lt	−	Non-ENI	65.0	#106recR	58.3	Chemotherapy
0	Mt	+	ENI	40.0	Local	75.1	ESD

Lymph node metastasis was recorded according to the Japanese Society for Esophageal Diseases classification of esophageal cancer, 10th edition. #104: supraclavicular LNs (lymph nodes), #3: LNs along the lesser curvature, #7: LNs along the left gastric artery, #101: cervical paraesophageal LNs, #109: main bronchus LNs, #106rec: recurrent nerve LNs. DFS disease-free survival (months), Dose radiotherapy dose (Gy), ER endoscopic resection, ESD endoscopic submucosal dissection, Lt lower thoracic esophagus, Mt middle thoracic esophagus, PS Performance status, RT field radiotherapy field, Ut upper thoracic esophagus

ISSN: 1748-717X